Adrenocortical carcinoma laboratory findings: Difference between revisions

Jump to navigation Jump to search
 
Line 29: Line 29:
|'''Epinephrine'''<ref name="pmid21385478">{{cite journal| author=Song G, Joe BN, Yeh BM, Meng MV, Westphalen AC, Coakley FV| title=Risk of catecholamine crisis in patients undergoing resection of unsuspected pheochromocytoma. | journal=Int Braz J Urol | year= 2011 | volume= 37 | issue= 1 | pages= 35-40;discussion 40-1 | pmid=21385478 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21385478  }}</ref>
|'''Epinephrine'''<ref name="pmid21385478">{{cite journal| author=Song G, Joe BN, Yeh BM, Meng MV, Westphalen AC, Coakley FV| title=Risk of catecholamine crisis in patients undergoing resection of unsuspected pheochromocytoma. | journal=Int Braz J Urol | year= 2011 | volume= 37 | issue= 1 | pages= 35-40;discussion 40-1 | pmid=21385478 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21385478  }}</ref>
|
|
* [[Metanephrine]] and [[normetanephrine]] in plasma or 24-hour urine  
* [[Metanephrine]] and [[normetanephrine]] in the plasma or 24-hour urine  
|-
|-
|'''Aldosterone'''<ref name="pmid21917861">{{cite journal| author=Arlt W, Biehl M, Taylor AE, Hahner S, Libé R, Hughes BA et al.| title=Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. | journal=J Clin Endocrinol Metab | year= 2011 | volume= 96 | issue= 12 | pages= 3775-84 | pmid=21917861 | doi=10.1210/jc.2011-1565 | pmc=3232629 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21917861  }}</ref>
|'''Aldosterone'''<ref name="pmid21917861">{{cite journal| author=Arlt W, Biehl M, Taylor AE, Hahner S, Libé R, Hughes BA et al.| title=Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. | journal=J Clin Endocrinol Metab | year= 2011 | volume= 96 | issue= 12 | pages= 3775-84 | pmid=21917861 | doi=10.1210/jc.2011-1565 | pmc=3232629 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21917861  }}</ref>
|
|
* Low serum [[aldosterone]] concentrations, normal or high serum or urinary concentrations of aldosterone precursors  
* Low serum [[aldosterone]] concentrations, normal or high serum or urinary concentrations of [[aldosterone]] precursors  
|}
|}



Latest revision as of 16:43, 19 October 2017

Adrenocortical carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Adrenocortical carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

MRI

CT

Ultrasound

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Radiation Therapy

Primary prevention

Secondary prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Study

Case #1

Adrenocortical carcinoma laboratory findings On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Adrenocortical carcinoma laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adrenocortical carcinoma laboratory findings

CDC on Adrenocortical carcinoma laboratory findings

Adrenocortical carcinoma laboratory findings in the news

Blogs on Adrenocortical carcinoma laboratory findings

Hospitals Treating Adrenocortical carcinoma

Risk calculators and risk factors for Adrenocortical carcinoma laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2] Mohammed Abdelwahed M.D[3]

Overview

Patients with functional adrenocortical carcinoma may have elevated concentrations of serum cortisol, aldosterone, testosterone or estrogen and reduced concentration of plasma renin and potassium.

Laboratory Findings

Laboratory findings consistent with adrenocortical carcinoma are:

Hormonal disturbance labs
Cortisol[1]
Steroids[2]
Epinephrine[3]
Aldosterone[4]
  • Low serum aldosterone concentrations, normal or high serum or urinary concentrations of aldosterone precursors

References

  1. Dunlap NE, Grizzle WE, Siegel AL (1985). "Cushing's syndrome. Screening methods in hospitalized patients". Arch Pathol Lab Med. 109 (3): 222–9. PMID 3838451.
  2. Fassnacht M, Allolio B (2009). "Clinical management of adrenocortical carcinoma". Best Pract Res Clin Endocrinol Metab. 23 (2): 273–89. doi:10.1016/j.beem.2008.10.008. PMID 19500769.
  3. Song G, Joe BN, Yeh BM, Meng MV, Westphalen AC, Coakley FV (2011). "Risk of catecholamine crisis in patients undergoing resection of unsuspected pheochromocytoma". Int Braz J Urol. 37 (1): 35–40, discussion 40-1. PMID 21385478.
  4. Arlt W, Biehl M, Taylor AE, Hahner S, Libé R, Hughes BA; et al. (2011). "Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors". J Clin Endocrinol Metab. 96 (12): 3775–84. doi:10.1210/jc.2011-1565. PMC 3232629. PMID 21917861.

Template:WH Template:WS